Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate C...
August 24 2016 - 9:00AM
Business Wire
Chosen from among numerous larger labs based on
quality and reliability
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announces that the Company has entered into a services agreement
with an unnamed global pharmaceutical company to provide
Fluorescence in Situ Hybridization (FISH) testing services for a
clinical study the pharmaceutical company is conducting in prostate
cancer.
The study will use FISH to determine the phosphatase and tensin
homolog (PTEN) gene status of a number of prostate adenocarcinoma
cases. The concordance of the FISH results will be assessed for
cases where PTEN status was previously established by
immunohistochemistry (IHC). The primary goal of the study is to
determine if PTEN by FISH detects cancers that IHC did not.
“We are very pleased to have our FISH testing selected by this
global pharmaceutical for their clinical testing study. The
quality, reliability and turn-around time of our best-in-class FISH
testing enabled us to win this important business. It has also
allowed us to gain business from a number of sizeable customers who
were not happy with the quality and reliability of FISH test
offerings of certain larger competitors. For example, we won the
business of one large statewide health care provider after we
succeeded in providing correct diagnoses on a number of samples
that a large competitor was unable to achieve. In addition, we also
took a large state university hospital’s HEME FISH business from
another competitor based on our FISH tests’ high quality,
reliability and timeliness,” stated Kenneth A. Berlin, President
and Chief Executive Officer of Rosetta Genomics.
The FISH service offered by RosettaGX is best-in-class, with a
highly competitive success rate in obtaining informative results in
98% of cases, and a turnaround time of 3 to 4 days.
Rosetta’s FISH technology is used for the early detection of
genomic changes, which may detect cancer, measure the potential
aggressiveness of the disease, and identify if patients are likely
to respond to specific targeted therapies
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs. For more information
visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including, but not limited to
statements relating to our ability to obtain new business
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta’s most recently
filed Annual Report on Form 20-F, as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Rosetta does
not assume any obligation to update any forward-looking statements
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160824005496/en/
Rosetta GenomicsKen Berlin, President & CEO(267)
298-1159investors@rosettagx.comorRosetta Genomics
Investor:LHAAnne Marie Fields(212) 838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024